Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.

Clinical therapeutics - 1 Jul 2012

Ravnan Marcus C, Matalka Mazen S

Abstract excerpt

BACKGROUND: Vemurafenib is an oral, small-molecule kinase inhibitor that selectively targets activated BRAF V600E and has been approved for the treatment of advanced BRAF mutation-positive melanoma. OBJECTIVE: This article reviews the clinical pharmacology, efficacy, tolerability, and pharmacokinetics of vemurafenib and in addition outlines proposed mechanisms of vemurafenib resistance. METHODS: A literature...

Topics

Antineoplastic Agents
Disease-Free Survival
Drug Resistance, Neoplasm
Humans
Indoles
Melanoma
Mutation
Proto-Oncogene Proteins B-raf
Skin Neoplasms
Sulfonamides
Survival Rate
Treatment Outcome

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Vemurafenib

Source

Identifiers

PMID: 22742884
DOI: 10.1016/j.clinthera.2012.06.009

Genes

BRAF
BID

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.PMID 22742884Read ↗

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.Semantic proximity Read ↗

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.Semantic proximity Read ↗

Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaSemantic proximity Read ↗

Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Semantic proximity Read ↗

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.Semantic proximity Read ↗

Vemurafenib: the road to personalized medicine in melanoma.Semantic proximity Read ↗

Vemurafenib.Semantic proximity Read ↗

Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.Semantic proximity Read ↗

Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies.Semantic proximity Read ↗

Vemurafenib (PLX4032): an orally available inhibitor of mutated BRAF for the treatment of metastatic melanoma.Semantic proximity Read ↗

Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.